申请人:ENI-Ente Nazionale Idrocarburi
公开号:EP0115091A1
公开(公告)日:1984-08-08
This invention relates to compounds useful as active principles of formula 1 in the treatment of hypertension, and to processes for their preparation.
where
R' and R4, equal or different, are hydrogen, alkyl substituted alkyl, aryl, aralkyl or alkyl substituted with an heterocyclic radical,
R2 is hydrogen, alkyl, aryl or aralkyl;
R3 and R5, equal or different, are hydroxy, substituted hydroxy amino, substituted amino, X is
where R6 and R7, equal or different, are hydrogen, alkyl or aralkyl;
A is the residue
where n and m are 1 or 2 and m+n is 2 or 3, Y is either -0-or -S- and R8 is aryl, a heterocyclic radical, acyl, arylsulphonyl, alkylsulphonyl, trialkylsilyl, nitro, cyclic saturated alkyl, cyclic or non-cyclic unsaturated alkyl, substituted alkyl, aralkyl; or alkyl substituted with a heterocyclic radical; when Y is -S-, R8 can also be hydrogen or non-cyclic saturated alkyl;
where m and n are 1 or 2 and m+n is 2 or 3; R9 and R10, equal or different, are hydrogen, alkyl, substituted alkyl, aryl, aralkyl or alkyl substituted with an heterocyclic radical, and in which the alkyl portion can also comprise an amino or acylamino substituent;
and R" is hydroxy, substituted hydroxy, carboxy or substituted carboxy, eneoxycabonyl, aryloxycarbonyl, amino, substituted amino, substituted alkyl; the asterisks indicating asymmetric carbon atoms; and the pharmaceutically acceptable salts of said derivatives.
本发明涉及作为治疗高血压的活性成分的式 1 化合物及其制备工艺。
其中
R'和 R4,相同或不同,是氢、取代的烷基、芳基、芳烷基或被杂环基取代的烷基、
R2 是氢、烷基、芳基或芳烷基;
R3 和 R5,相同或不同,是羟基、取代羟基的氨基、取代氨基,X 是
其中 R6 和 R7(相同或不同)是氢、烷基或芳烷基;
A 是残基
其中 n 和 m 为 1 或 2,m+n 为 2 或 3,Y 为-0-或-S-,R8 为芳基、杂环基、酰基、芳基磺酰基、烷基磺酰基、三烷基硅基、硝基、环状饱和烷基、环状或非环状不饱和烷基、取代烷基、芳烷基;或被杂环基取代的烷基;当 Y 为-S-时,R8 也可以是氢或非环状饱和烷基;
其中 m 和 n 为 1 或 2,m+n 为 2 或 3;R9 和 R10 相同或不同,为氢、烷基、取代烷基、芳基、芳烷基或被杂环基取代的烷基,其中烷基部分还可以包括氨基或酰氨基取代基;
R "是羟基、取代的羟基、羧基或取代的羧基、烯氧羰基、芳氧羰基、氨基、取代的氨基、取代的烷基;星号表示不对称碳原子;以及所述衍生物的药学上可接受的盐。